HAL (France)
open access
Saccharin-Enabled Oral Formulation, Biopharmaceutics and Early Genotoxicity Assessment of the PPARγ Antagonist T0070907
Background/Objectives: T0070907 is a potent PPARγ antagonist with emerging antitumour activity in osteosarcoma; however, its very low aqueous solubility, uncertain systemic exposure, and nitroaromatic structure raise significant developability concerns. This work aimed to convert T0070907 into a pha
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation#877884
- Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)#901128
- A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors#892962
- Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors#1009857
- Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis#869319
Record · ID 1235246
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive